Bruce Cree, AAN 2022: Bruton tyrosine kinase inhibitors in multiple sclerosis – Key clinical highlights
Prof. Bruce Cree (UCSF Multiple Sclerosis Centre, San Francisco, CA, USA) discusses the potential use of bruton tyrosine kinase inhibitors (BTKis) in the treatment of multiple sclerosis. Prof. Cree discusses BTKis novel mechanism of action and the rationale behind the investigation of this new class of drugs.
Question: What are the key clinical highlights in the treatment of multiple sclerosis?
View more content from Prof. Bruce Cree:
Bruce Cree, AAN 2022: Ublituximab and its potential use in the treatment of relapsing multiple sclerosis
Bruce Cree, AAN 2022: Disability improvements with ublituximab in relapsing multiple sclerosis – Phase 3 ULTIMATE I and II
Disclosures: Bruce Cree is a consultant for Alexion, Atara, Autobahn, Avotres, Biogen, EMD Serono, Gossamer Bio, Horizon, Neuron23, Novartis, Sanofi, TG Therapeutics and Therini; and receives grant/research support from Genentech; and is also on the advisory board for Autobahn.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In Multiple Sclerosis
Barry Singer, ECTRIMS 2022: Diroximel fumarate for relapsing-remitting multiple sclerosis – Phase 3 results from EVOLVE-MS-1
The phase 3 EVOLVE-MS-1 (NCT02634307), was a 96-week, open-label, Phase 3 study, assessing safety, tolerability, and exploratory clinical and MRI efficacy of diroximel fumarate in adults with relapsing-remitting multiple sclerosis (RRMS). Diroximel fumarate, an oral fumarate for relapsing-remitting multiple sclerosis, has the same active metabolite as dimethyl fumarate. Diroximel fumarate has similar efficacy and safety […]
Barry Singer, ECTRIMS 2022: Flushing and GI adverse events in RRMS patients on diroximel fumarate – Analysis from phase 3 EVOLVE-MS-1 study
The phase 3 EVOLVE-MS-1 (NCT02634307), was a 96-week, open-label, Phase 3 study, assessing safety, tolerability, and exploratory clinical and MRI efficacy of diroximel fumarate in adults with relapsing-remitting multiple sclerosis (RRMS). Diroximel fumarate, an oral fumarate for relapsing-remitting multiple sclerosis, has the same active metabolite, and similar efficacy and safety to dimethyl fumarate but with […]
Dominic Shadbolt: ECTRIMS Patient perspective – Lifestyle interventions as part of a management plan for MS
We welcome Dominic Shadbolt, a patient advocate in multiple sclerosis (MS), and founder of theMSguide.com. Dominic joins touchNEUROLOGY to share his perspective on being a patient advocate at the annual ECTRIMS congress, and highlights from the most salient presentations. In this interview, Dominic highlights the lifestyle interventions that people living with MS can undertake as […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!